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IGRT to particle therapy. Proton therapy offers dosimetric advantages 
not possible with x-rays but with a relative biologic effectiveness quite 
close to photons. Thus, normal tissue tolerances can rely on 100 years 
of laboratory and clinical experiences. Well-established indications for 
proton therapy include ocular melanomas, cancer in children, brain 
tumors, sarcomas and chordomas at the base of the skull and carcinoma 
of the prostate. There are many opportunities for proton therapy with 
concurrent chemotherapy to improve the therapeutic ratio compared 
with x-irradiation. There is considerable potential to increase doses 
in tumors without increasing toxicity for common diseases such as 
cancer of the lung. The value of proton therapy is just beginning to be 
recognized.
Interest in proton therapy has increased dramatically around the world. 
Japan alone has six clinical proton therapy centers. Four hospital-based 
proton centers are treating patients in the United States and several 
others are being planned. The beneﬁcial results of 3D over 2D RT, and 
of IMRT over 3DCRT contribute to a compelling case for proton beam 
therapy. As proton therapy equipment becomes less costly and smaller 
and results of proton therapy are published, one can envision a robust 
role for proton beam therapy in the future of cancer treatment.
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Systemic therapy improves survival and quality of life for patients 
with advanced stage non-small cell lung cancer (NSCLC). It became 
clear that infact a ëchemotherapy efﬁcacy plateauí had been reached 
when comparison of multiple two-drug combinations failed to show 
any beneﬁt of one over another. The role of prolonged or maintenance 
therapy beyond 3-6 cycles was challenged by the results from two 
large randomized phase III studies, but there was an apparent ﬂaw as 
majority of the patients randomized to longer duration of chemotherapy 
did not receive the planned number of cycles, leading to discontinua-
tion either due to toxicity or disease progression. Therefore, one could 
only conclude that continuation of combination chemotherapy (two or 
three drugs) beyond 4 cycles is not a feasible option. A number of new 
therapeutic options have subsequently emerged during recent times 
for advanced NSCLC incorporating novel cytotoxic agents (taxanes, 
gemcitabine, pemetrexed) and targeted agents (erlotinib, bevacizumab). 
Efforts to improve the outcome for front-line therapy of advanced and 
metastatic NSCLC have primarily focused on the addition of molecu-
larly targeted agents to platinum-based two drug regimens. Bevaci-
zumab, an antibody against the vascular endothelial growth factor, is 
the ﬁrst drug to demonstrate improvement in outcome when added to 
systemic chemotherapy in advanced disease. Since bevacizumab was 
given as monotherapy following initial response or disease stabilization 
on ECOG 4599, it is now used in the maintenance setting for advanced 
NSCLC. This has led to new insight and a glimmer of hope debate 
for the role of maintenance therapy in advanced NSCLC, provided it 
is not associated with any signiﬁcant long term adverse effects. Both 
cytotoxic single agents and molecularly targeted agents are suited for 
evaluation in the maintenance setting. Promising results have been 
noted with single agent paclitaxel as maintenance therapy following 4 
cycles of combination therapy with carboplatin and paclitaxel. Phase 
III studies are now underway to evaluate the role of single agents such 
as gemcitabine, pemetrexed and erlotinib(ﬁgures 1-3) as maintenance 
therapy for patients who experience a response or disease stabilization 
following 4 cycles of combination chemotherapy. Whether this ap-
proach will be successful in extending the survival of a select group of 
patients remains to be seen. It does, in fact, takes maximal advantage of 
either known active agents in this disease or novel agents which have 
shown early evidence of provocative activity.
In addition to the evaluation of newer agents to improve the outcome 
for advanced NSCLC, maintenance therapy represents a novel strategy 
to increase the therapeutic potential of currently available agents and 
commonly used regimens. Multiple lines of evidence from recent 
observations suggest that maintenance therapy with well tolerated che-
motherapeutic or targeted agents may beneﬁt patients with advanced 
NSCLC. This also has the potential to improve the toxicity proﬁle of 
overall treatment as combination chemotherapy would then be limited 
to 4 cycles and maintenance therapy would be essentially without any 
signiﬁcant adverse effects if chosen optimally. Since maintenance ther-
apy utilizes currently available agents, it may also be associated with 
better cost-beneﬁt ratio. In the next 1-2 years, the results from several 
ongoing trials that focus on maintenance therapy will be available. It is 
hoped that the data will usher in a new treatment paradigm for patients 
with advanced stage NSCLC.
